* Cidara Therapeutics Inc is expected to show a fall in quarterly revenue when it reports results on May 9 (estimated) for the period ending March 31 2024
* The San Diego California-based company is expected to report a 75.8% decrease in revenue to $6.3 million from $25.99 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Cidara Therapeutics Inc is for a loss of 20 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Cidara Therapeutics Inc is $40.00, above its last closing price of $13.61.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -3.19 -2.07 -0.80 Beat 61.3
Jan. 1 2023 -3.19 -3.25 -1.80 Beat 44.6
Jan. 1 0001 -2.04 -2.60 -2.80 Missed -7.7
Mar. 31 2023 -4.24 -0.73 0.60 Beat 181.8
Jan. -4.24 -3.35 -3.80 Missed -13.4
1 0001
Sep. 30 2022 3.71 -5.60 3.40 Beat -5.6
Jan. 1 0001 -5.59 -5.60 -3.80 Beat 32.1
Mar. 31 2022 -5.54 -5.40 8.2
This summary was machine generated May 7 at 12:11 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments